Finally, our findings will provide a rationale to develop a new class of drug to disrupt asymmetric dimerization, which would be potent to treat a subset of cancer patients harboring dimerization-dependent oncogenic EGFR mutants including C-terminal deletion mutants. This evidence concerns the gene EGFR and cancer.